Cargando…

Novel mechanisms of anti-hypertrophic effects from PDE5A inhibition

Detalles Bibliográficos
Autores principales:	Kass, David A, Nagayama, Norimichi, Zhang, Manling, Lee, Dong-ik, Hsu, Steven, Ketner, Elizabeth, Takimoto, Eiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313408/ http://dx.doi.org/10.1186/1471-2210-9-S1-S18

Ejemplares similares

Benefits of PDE5 inhibition in patients with diastolic heart failure
por: Guazzi, Marco
Publicado: (2011)

cGMP-PKG upregulates PGC1α and improves cardiac function in advanced cardiac hypertrophy independently of RGS2
por: Takimoto, Eiki
Publicado: (2011)

cGMP kinase I, cardiac hypertrophy and PDE inhibition
por: Patrucco, Enrico, et al.
Publicado: (2011)

cGMP-Prkg1 signaling PDE5 inhibition shelter cochlear hair cells and hearing function
por: Knipper, Marlies, et al.
Publicado: (2013)

Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy
por: Rybalkin, Sergei D, et al.
Publicado: (2013)

Molecular targets for PDE inhibitor-mediated improvement of cardiac dysfunction in the mdx mouse?
por: Adamo, Candace M, et al.
Publicado: (2011)

Acute effects of phosphodiesterase 5 (PDE5) inhibition, ANP and NO on epididymal contractility are preserved despite chronic PDE5 exposure
por: Mietens, Andrea, et al.
Publicado: (2011)

Diffuse myocardial fibrosis in pediatric hypertrophic cardiomyopathy
por: Hussain, Tarique, et al.
Publicado: (2013)

T1 mapping in discrimination between hypertrophic and hypertensive cardiomyopathy
por: Hinojar, Rocio, et al.
Publicado: (2014)

Polymorphism in HIV-1 dependency factor PDE8A affects gene expression and HIV-1 replication in primary macrophages
por: Booiman, Thijs, et al.
Publicado: (2011)

Clinical significance of late gadolinium enhancement in pediatric patients with hypertrophic cardiomyopathy
por: Smith, Brandon M, et al.
Publicado: (2013)

Incremental predictive value of deep crypts in the basal inferoseptum in the setting of hypertrophic cardiomyopathy
por: Deva, Djeven P, et al.
Publicado: (2013)

Preclinical alterations in cardiac energetics amongst sarcomere mutation carriers in hypertrophic cardiomyopathy
por: Lloyd, Rachael, et al.
Publicado: (2015)

Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011)

Myocardial T2 signal enhancement in hypertrophic cardiomyopathy: prevalence, clinical profile and pathologic correlation
por: Kolman, Louis, et al.
Publicado: (2014)

A combined phase I/IIa study of the safety, bronchodilator and bronchoprotective effects of nebulized RPL554, a dual PDE3/4-inhibitor, in healthy subjects and asthmatics
por: Franciosi, Luigi, et al.
Publicado: (2013)

Screening for hypertrophic cardiomyopathy: a cost analysis of echocardiography, cardiac magnetic resonance and genetic testing
por: Hauser, Thomas H, et al.
Publicado: (2009)

Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy
por: Fukuma, Nobuaki, et al.
Publicado: (2020)

Late gadolinium enhancement cardiovascular magnetic resonance for sudden cardiac death risk stratification in hypertrophic cardiomyopathy
por: Ismail, Tevfik F, et al.
Publicado: (2013)

Advanced assessment of cardiac morphology and prediction of gene carriage by CMR in hypertrophic cardiomyopathy - the HCMNet/UCL collaboration
por: Captur, Gaby, et al.
Publicado: (2014)

Protein kinase G I alpha activates an anti-remodeling signaling pathway in the heart via an interaction with the MAPKKK mixed lineage kinase 3
por: Blanton, Robert M, et al.
Publicado: (2011)

Role of T1 and T2-mapping in assessing the myocardial interstitium in hypertrophic cardiomyopathy: a cardiovascular magnetic resonance study
por: Ismail, Tevfik F, et al.
Publicado: (2013)

A new variant of apical hypertrophic cardiomyopathy? T wave inversion and relative but not absolute apical left ventricular hypertrophy
por: Flett, Andrew, et al.
Publicado: (2013)

TRIM5alpha contributes to the anti-viral state
por: Pertel, Thomas, et al.
Publicado: (2009)

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets
por: Rybalkina, Irina G, et al.
Publicado: (2011)

Non-contrast T1 mapping characterizes the myocardium beyond that achieved by late gadolinium enhancement in both hypertrophic and dilated cardiomyopathy
por: Dass, Sairia, et al.
Publicado: (2012)

A systematic review for sudden cardiac death in hypertrophic cardiomyopathy patients with myocardial fibrosis: a CMR LGE study
por: Silva, Nackle J, et al.
Publicado: (2012)

Derangement of cardiac energy metabolism is acutely exacerbated during exercise in hypertrophic cardiomyopathy, independent of hypertrophy or late gadolinium burden
por: Dass, Sairia, et al.
Publicado: (2012)

T1 measurements identify extracellular volume expansion in a genotyped hypertrophic cardiomyopathy population with and without left ventricular hypertrophy
por: Abbasi, Siddique, et al.
Publicado: (2013)

Inhibition of the T cell oxygen sensing machinery promotes anti-tumor efficacy
por: Clever, David, et al.
Publicado: (2015)

Characterization of patients with massive hypertrophic cardiomyopathy using contrast-enhanced magnetic resonance imaging: does contrast provide additional information?
por: Chan, Raymond H, et al.
Publicado: (2012)

Phosphodiesterase-5 inhibition and cardioprotection: potential role of hydrogen sulfide
por: Kukreja, Rakesh C, et al.
Publicado: (2009)

OA21 Are novel anti-IL5 biologics triggering rheumatoid arthritis?
por: Dean, Nathan, et al.
Publicado: (2023)

Characterization of tissue heterogeneity by contrast-enhanced cardiovascular magnetic resonance imaging is a powerful predictor of ventricular tachyarrhythmias on ambulatory holter ECG in hypertrophic cardiomyopathy
por: Harrigan, Caitlin J, et al.
Publicado: (2009)

T2 abnormalities in patients with hypertrophic cardiomyopathy characterized by cardiovascular magnetic resonance imaging- an indicator of myocardial injury as assessed by the high sensitive cardiac troponin T assay
por: Lehrke, Stephanie, et al.
Publicado: (2012)

Quantitative of myocardial extracellular volume fraction improves characterization of fibrotic burden in patients with apical hypertrophic cardiomyopathy beyond visual assessment with late gadolinium enhancement
por: Watanabe, Eri, et al.
Publicado: (2012)

PDE3 is the major cGMP-PDE in adult mouse ventricular cardiomyocytes
por: Götz, Konrad R, et al.
Publicado: (2013)

OA16 A case of anti-MDA5 dermatomyositis: the challenge of atypical skin manifestations
por: Biddle, Kathryn, et al.
Publicado: (2023)

Subtle structural abnormalities in genotype positive phenotype ‘negative’ patients with pre-clinical hypertrophic cardiomyopathy (HCM): a blinded, controlled cardiovascular magnetic resonance (CMR) study
por: Deva, Djeven, et al.
Publicado: (2012)

2. Two cases of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease
por: Levasseur, Kirsty, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2btmjql9gqq7e4mt6ltsugc1o7